Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
about
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosisA proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosisLevels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments.Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosisMediators leading to fibrosis - how to measure and control them in tissue engineering.Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander?Angiogenic activity of sera from pulmonary tuberculosis patients in relation to IL-12p40 and TNFα serum levelsAngiogenic activity of sera from interstitial lung disease patients in relation to pulmonary functionMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosisControl of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice.Effect of different interferonα2 preparations on IP10 and ET-1 release from human lung cells.Pulmonary hypertension in parenchymal lung disease.Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis.Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapyAngiogenic activity of sera from interstitial lung disease patients in relation to clinical and radiological changes.Clinical implications for vascular endothelial growth factor in the lung: friend or foe?Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.The inter-connection between fibrosis and microvascular remodeling in idiopathic pulmonary fibrosis: Reality or just a phenomenon.Serum inter-alpha-trypsin inhibitor and matrix hyaluronan promote angiogenesis in fibrotic lung injury.VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.Serum vascular endothelial growth factor in pediatric patients with community-acquired pneumonia and pleural effusion.The pathogenesis of idiopathic pulmonary fibrosis.Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.Physiological and pathological angiogenesis in the adult pulmonary circulation.Molecular biomarkers in interstitial lung diseases.Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.Pulmonary hypertension associated with lung diseases and hypoxemia.Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis.Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema.VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease.
P2860
Q26750418-57760620-88AD-4A00-89BD-D448896D8AB4Q28383207-69D299A9-E818-4581-9346-88A81DA79F78Q30398970-3D0CF652-EE9F-402B-9D7A-258DC7E1B288Q33732623-4B5C8C23-C974-40D7-B148-0129447EC918Q34159587-114898E1-CEF2-4693-94A3-D0396D899C3AQ34882979-4EEC0D65-4F55-46E8-B353-8A3EE26F12BFQ35120028-AD5B1B1E-5615-4368-9B8F-63224DC30640Q35179145-B470945C-8F95-4274-B8F7-D6B1186C262FQ35558781-1F8CBDCC-58A8-41E7-8E6B-1961A59799D7Q35855163-2353B227-B17A-4F27-AE15-0C942CC5DA92Q36303468-9D4F7AB2-BA70-49F6-9A91-487946309734Q36328903-6CA19784-74C1-446B-A4A0-61A083F52DB7Q36390205-4E1499A3-D10D-4C40-B939-779676C8C8ABQ36440438-5FBA033B-D0DF-4E59-852E-0BC6E760F620Q36464112-30D69010-D824-41B0-9950-DF9C9C6D1E82Q36625050-0B733132-B7C0-467A-B9FA-A690523CD007Q36719113-44DCEA98-ADFD-4B19-B7C9-9856E3C8D60CQ36766700-65593D8D-42BB-4F45-A308-0E53FD588D79Q36960794-9E11550E-FA9F-4406-B625-BC83C8579702Q37170742-98B1241A-62D0-42D3-90B7-DE805F68EC38Q37313133-9CE43342-3A7B-4D25-ABF1-C92340899062Q37800756-B0ACDE90-D553-4BB1-9B06-784DBA936282Q37937430-812FD565-F79F-448E-A0D7-996290B9369AQ38111715-444E2A80-D7D7-43B4-9627-B01BC21C1113Q38220769-11496419-F8DA-41E2-A00F-68579B89F6D1Q38538687-28458613-EC97-416E-AB1A-4988E6266717Q38810145-F57E0A35-C658-4A4A-B043-5A6F7E08A3CEQ38981777-519D3FA8-F27E-42BF-9FB0-96F448B915F2Q39401141-6BCADCB5-FD6F-4AFE-9C70-325F33EE7C0FQ41703248-AA425C52-F70D-42D0-8727-B3F99A3BCE9DQ51226432-5B7586EA-7137-4E6A-AC35-E6E370D6D76AQ52309706-CC8C1D3B-E0DC-44F9-BB54-BBE94BD74FB0
P2860
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@ast
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@en
type
label
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@ast
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@en
prefLabel
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@ast
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@en
P2093
P2860
P356
P1433
P1476
Angiogenic cytokines in patients with idiopathic interstitial pneumonia.
@en
P2093
Brenchley PE
Greaves SM
Hasleton PS
Horrocks AW
P2860
P304
P356
10.1136/THX.2003.009860
P407
P577
2004-07-01T00:00:00Z